• Establishment Labs Holdings Inc. (NASDAQ:ESTA) exceeded the Zacks Consensus Estimate for quarterly loss, posting a positive surprise of 29.63%.
• The company reported a revenue of $53.78 million for Q3 2025, surpassing the Zacks Consensus Estimate by 3.45%.
• Despite volatility, ESTA's stock price reflects investor confidence, with a 7.27% increase to $64.91, near its 52-week high.

Establishment Labs Holdings Inc. (NASDAQ:ESTA) is a prominent player in the medical technology sector, focusing on women's health, particularly in breast aesthetics and reconstruction. The company has recently been in the spotlight due to Needham's price target of $70, set on November 6, 2025. At that time, ESTA's stock was priced at $64.91, suggesting a potential increase of 7.84%.

The company's recent Q3 2025 earnings call, held on November 5, 2025, provided valuable insights into its financial performance. Key figures such as CFO Rajbir Denhoy and CEO Filippo Caldini participated, alongside representatives from major financial institutions. The call highlighted a quarterly loss of $0.38 per share, which was better than the Zacks Consensus Estimate of a $0.54 loss, marking a positive surprise of 29.63%.

In terms of revenue, Establishment Labs reported $53.78 million for the quarter ending September 2025. This figure exceeded the Zacks Consensus Estimate by 3.45% and represented a significant growth from the $40.23 million in revenue from the same period last year. The revenue growth was driven by sales of their Motiva products, contributing $11.9 million.

Despite the positive earnings surprise, the company has only exceeded consensus revenue estimates once in the last four quarters. However, the 33.8% increase in revenue compared to the previous year demonstrates the company's strong market position and growth potential. The stock's recent performance, with a 7.27% increase to $64.91, reflects investor confidence in the company's future prospects.

ESTA's stock has shown significant volatility, with a 52-week high of $65.10 and a low of $26.56. The current market capitalization stands at approximately $1.88 billion, with a trading volume of 1,341,361 shares. As the company continues to exceed earnings expectations, investors remain optimistic about its growth trajectory in the medical technology industry.